Clinical Use of Mesenchymal Stromal Cells in the Treatment of Acute Graft-versus-Host Disease
Open Access
- 4 February 2019
- journal article
- review article
- Published by S. Karger AG in Transfusion Medicine and Hemotherapy
- Vol. 46 (1) , 27-34
Abstract
Acute graft-versus-host disease (aGvHD) continues to impact morbidity and mortality after allogeneic stem cell transplantation (allo-SCT). First-line therapy for aGvHD still remains the use of high-dose corticosteroids. Unfortunately, 40–60% of patients with aGvHD exhibit steroid resistance, which is associated with a very poor prognosis. As no effective second-line therapy existed, in recent decades various treatment options were considered for the treatment of therapy-refractory GvHD. Based on their in vitro immunomodulatory properties, the use of mesenchymal stromal cells (MSCs) in the treatment of aGvHD has been introduced. However, most of the clinical data are generated from uncontrolled trials and case series, showing clinical responses to MSCs. Clinical results are more consistent in children despite the use of MSC preparations of various provenance and manufacturing protocols. While these data support the therapeutic principle, the great variability of outcomes strongly suggests that not all MSC preparations are equal and that the specific manufacturing protocols influence therapeutic success in vivo.Keywords
This publication has 40 references indexed in Scilit:
- Transplant‐related mortality following allogeneic hematopoeitic stem cell transplantation for pediatric acute lymphoblastic leukemia: 25‐year retrospective reviewPediatric Blood & Cancer, 2013
- Basic Biology and Clinical Application of Multipotent Mesenchymal Stromal Cells: From Bench to BedsideStem Cells International, 2012
- Multipotent mesenchymal stromal cells and the innate immune systemNature Reviews Immunology, 2012
- Long-Term Complications, Immunologic Effects, and Role of Passage for Outcome in Mesenchymal Stromal Cell TherapyTransplantation and Cellular Therapy, 2012
- Efficacy and Safety of Ex Vivo Cultured Adult Human Mesenchymal Stem Cells (Prochymal™) in Pediatric Patients with Severe Refractory Acute Graft-Versus-Host Disease in a Compassionate Use StudyTransplantation and Cellular Therapy, 2011
- Mesenchymal stem cells expanded in vitro with human serum for the treatment of acute and chronic graft-versus-host disease: results of a phase I/II clinical trialHaematologica, 2011
- Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing mediumBone Marrow Transplantation, 2008
- Mesenchymal Stem Cells for Treatment of Therapy-Resistant Graft-versus-Host DiseaseTransplantation, 2006
- Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statementCytotherapy, 2006
- HETEROTOPIC TRANSPLANTS OF BONE MARROWTransplantation, 1968